Laigo's proprietary SureTAC platform empowers us to rapidly develop first-in-class dual targeted therapies that eliminate disease-driving membrane targets using straightforward bispecific antibody technology. We are committed to exploring an ever-evolving universe of new targets, including those currently considered undruggable, and we are open to strategic partnerships to make meaningful advancements in treating diseases that lack effective treatment options today. Laigo Bio is where innovation meets life-changing solutions, forging a path toward a healthier tomorrow. #TPD #Protac #membraneprotein #bispecificantibody #antibody #proteindegradation #roteindegrader #LaigoBio #oncology #neurobiology #immunology #SureTACs
Location: Netherlands
Employees: 1-10
Total raised: $33.33M
Funding Rounds 2
| Date | Series | Amount | Investors |
| 31.03.2026 | Seed | $19.88M | Kurma Part... |
| 08.12.2025 | Seed | $13.45M | Angelini V... |
Mentions in press and media 9
| Date | Title | Description |
| 31.03.2026 | Laigo Bio Secures €17M: SureTACs Platform Targets Cancer, Autoimmune Diseases | Laigo Bio secured €17M seed funding for its SureTACs platform. The biotech pioneers precision membrane protein degradation. Funds will accelerate oncology programs to the clinic. They also advance autoimmune and immunology candidates. The i... |
| 31.03.2026 | Laigo Bio: €17 Million Raised For Biotech Developing SureTACs Precision Protein Degradation Platform | Laigo Bio, a Netherlands-based biotech company developing targeted protein degradation therapies, has completed the final close of its oversubscribed seed financing round, bringing the total raised to €17 million. The latest tranche include... |
| 23.03.2026 | Laigo Bio Closes €17M Seed Funding | Laigo Bio, an Utrecht, The Netherlands-based biotech company, closed the second close of its seed financing round, securing an additional €5.5m, bringing the total raised to €17m. This latest investment comes from new co-lead investor Biova... |
| 13.01.2026 | Avenue Biosciences Secures $5.7M for Protein Engineering Revolution | Avenue Biosciences secured $5.7 million in seed extension funding. The Finnish protein engineering firm scales its high-throughput platform. It combines AI and wet-lab biology. This technology optimizes therapeutic protein manufacturing. It... |
| 12.01.2026 | Finnish startup Avenue Biosciences secures €4.8 million to help drugmakers manufacture proteins more reliably | Helsinki-based Avenue Biosciences, a protein engineering technology company, today announced a Seed extension of €4.8 million ($5.7 million) to scale a high-throughput protein engineering tech that accelerates the discovery of protein-based... |
| 08.12.2025 | Laigo Bio: €11.5 Million Seed Round Raised To Advance SureTAC Platform | Laigo Bio has raised €11.5 million in seed financing to accelerate development of its SureTAC targeted protein degradation platform. The company plans to use the funding to push its oncology programs toward clinical readiness and expand dis... |
| 04.12.2025 | Laigo Bio Raises €11.5M in Seed Financing | Laigo Bio, an Utrecht, The Netherlands-based company advancing novel therapies using its proprietary SureTAC™ precision membrane protein degradation platform, raised €11.5m in seed financing. x Please enable JavaScript x Please enable JavaS... |
| 04.12.2025 | Targeting the “undruggable”: Laigo Bio secures €11.5 million to advance its SureTAC protein degradation platform | Laigo Bio, an Utrecht-based company pioneering novel and highly differentiated therapies using its proprietary SureTAC precision membrane protein degradation platform, has successfully raised €11.5 million in Seed financing. The funding rou... |
| - | Laigo Bio | “Pioneering Protein Degradation for Targeted Therapies. Laigo Bio is at the forefront of a revolutionary era in biotechnology -one that offers new hope for eradicating disease-causing targets through protein degradation. Even targets that h... |